The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Open accessAbstract
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals. RESULTS: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed. CONCLUSIONS: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Family history of autoimmune diabetes and personal or family history of allergic diseases or other autoimmune diseases increases the risk of autoimmune diabetes compared with the general population (78,79).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, anti-CD3 treatment (teplizumab) has been shown to induce long-term protection (currently up to six years) from T1D in at-risk individuals, but the mechanisms responsible for this long-term protection remain incompletely understood29,30”
From An autoimmune stem-like CD8 T cell population drives type 1 diabetes (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“In one 2019 study with a 2year delay, annualised rates of clinical diabetes were 15% in the teplizumab group and 36% in the placebo group (table 1). 18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Teplizumab delays the onset of clinical type 1 diabetes by a median of 24 months.18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,000
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
Gurney, M. E., & Litzow, M. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19200-5.00003-8 · Cited by 2
Type 1 diabetes prevention and treatment: Time to think outside the box
Pinheiro, M. M., & Pinheiro, F. M. M. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13502 · Cited by 2
Al‐Horani, R. A., Aliter, K. F., & Aliter, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276832231124170324 · Cited by 2
Kostense, S., Klap, J. M., Ashoor, H., Yang, R., Weverling, G. J., Sweet, K., Rigby, M. R., & Hedrick, J. (2023) · medRxiv · doi:10.1101/2023.05.29.23290668 · Cited by 2
Aberrant TNF signaling in pancreatic lymph nodes of patients with Type 1 DiabetesPreprint
Abedi, M., Rai, P., Zhou, Y., Liu, C., Johnson, I., Chandra, A., Fasolino, M., Rostami, S. Y., Kaestner, K. H., Naji, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.31.596885 · Cited by 2
Brown, M. E., Thirawatananond, P., Peters, L. D., Kern, E. J., Vijay, S., Sachs, L. K., Posgai, A. L., Brusko, M., Shapiro, M. R., Mathews, C. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.16.603756 · Cited by 2
Inflammatory β-Cell Stress and Immune Surveillance in Type 1 DiabetesPreprint
Bhushan, A., & Thompson, P. J. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041605 · Cited by 4
Rebalancing the Immune System to Treat Type 1 DiabetesPreprint
Müller, Y. D., Ho, P., Bluestone, J. A., & Tang, Q. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041599 · Cited by 5
Self-citationIslet Autoantibody Testing as Type 1 Diabetes Early Detection Enters Mainstream Health Care
Gillespie, K. M. (2025) · Diabetes · doi:10.2337/dbi25-0016 · Cited by 2
Widener, A. E., Manson, C. T., Barra, J. M., Spencer, C. P., Grodman, A. D., Ladd, A. M., Russ, H. A., & Phelps, E. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.11.687837 · Cited by 2
Precision medicine in autoimmune disease
Deane, K. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820239-5.00005-x · Cited by 1
Type 1 diabetes mellitus prevention
Groele, L., & Szypowska, A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.134130 · Cited by 1
Mandile, R., Auricchio, R., Discepolo, V., & Troncone, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13359-6.00009-1 · Cited by 1
Serum proteomics of mother-infant dyads carrying HLA-conferred type 1 diabetes risk
Bhosale, S. D., Moulder, R., Suomi, T., Ruohtula, T., Honkanen, J. K., Virtanen, S. M., Ilonen, J., Elo, L. L., Knip, M., & Lahesmaa, R. (2024) · iScience · doi:10.1016/j.isci.2024.110048 · Cited by 1
An unmet need: Pancreatic beta cell replacement
Mohamed, F., Adams, C., & Mansfield, B. S. (2024) · South African Medical Journal · doi:10.7196/samj.2024.v114i3b.1249 · Cited by 2
Disease modifying therapies in diabetes and endocrinology
Mathieu, C. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00336-x · Cited by 1
Pyeritz, R. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-812531-1.00001-4 · Cited by 1
Fatulla, P., Ström, I., Lingblom, C., & Lind, M. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1494470 · Cited by 1
Clinical, biochemical and genetic characteristics of familial forms of type 1 diabetes
Zufarova, I. M., Лаптев, Д. Н., Minniakhmetov, I. R., Khusainova, R. I., Popov, S. V., Титович, Е. В., Eremina, I. A., & Peterkova, V. A. (2025) · Diabetes Mellitus · doi:10.14341/dm13200 · Cited by 1
Pharmacotherapy of type 1 diabetes – part 3: tomorrow
Rendell, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2468906 · Cited by 1
Mital, S., Haller, M. J., Schatz, D., & Nguyen, H. V. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0192 · Cited by 1
Self-citationLahn, V., Tittel, S. R., Ohlenschläger, U., Kamrath, C., Hammersen, J. E., Gellai, R., Mönkemöller, K., Dost, A., Bartelt, H., & Holl, R. W. (2025) · Pediatric Diabetes · doi:10.1155/pedi/9903467 · Cited by 1
Früherkennung des Typ-1-Diabetes im Kindesalter
Berge, T. V. D., Achenbach, P., Gemulla, G., Hummel, S., Loff, A., Kordonouri, O., & Fr1da-plex-Studiengruppe, D. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02202-z · Cited by 1
Latest Updates in Prevention and Screening of Type 1 Diabetes Mellitus
Citron-Zafrin, K., Gandica, R., & Leibel, N. I. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00351-z · Cited by 2
Lessons from Prediction and Prevention of Type 1 Diabetes
Speake, C., Lacy‐Hulbert, A., Lord, J. D., & Greenbaum, C. J. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf175 · Cited by 1
Self-citationTwenty years of progress in type 1 diabetes mellitus
Kay, T. W. H., & Couper, J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01177-x · Cited by 1
ATG as disease-modifying therapy for new-onset type 1 diabetes
Speake, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01773-8 · Cited by 1
Pancreatic transdifferentiation of NOD mouse livers prevented development of hyperglycemia
Mahoney, A. L. G., Ren, B., Nassif, N. T., O’Brien, B. A., Logan, G. J., Gorrie, C. A., Alexander, I. E., & Simpson, A. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.021 · Cited by 1
How Should an IBD Prevention Trial Be Designed?
Goetgebuer, R., Ungaro, R. C., Feagan, B. G., Jairath, V., Colombel, J., & D’Haens, G. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf212 · Cited by 1
Are We Ready With Prevention for Type 1 Diabetes?
Maines, E., Franceschi, R., Candia, F. D., & Mozzillo, E. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70101 · Cited by 3
Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function
Jenkins, B. J., Jenkins, Y. R., Ponce-Garcia, F. M., Moscrop, C., Perry, I. A., Hitchings, M. D., Uribe, A. H., Bernuzzi, F., Eastham, S., Cronin, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65417-4 · Cited by 2
General Population Screening for Type 1 Diabetes in Canada---CanScreenT1D
Senior, P. A., Marwaha, A., Witteman, H. O., Chakraborty, P. K., Hayeems, R. Z., & Wherrett, D. K. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.11.001 · Cited by 1
Self-citationSweeney, N. K., Atisha‐Fregoso, Y., Pozovskiy, R., Higdon, L. E., Anderson, M. S., Diamond, B., & Ridgway, W. M. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102684 · Cited by 1
CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored
Pattanaik, S. K., Rath, D., Moeini, A. M., & Nabi‐Afjadi, M. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00307-z · Cited by 1
Preparation and functional validation of rabbit anti-canine CD3ε monoclonal antibody
Li, H., Chen, M., Yue, R., Li, S., Shi, B., Qin, M., Meng, Q., & Xie, S. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1612069 · Cited by 1
Li, Z., Zhao, M., Luo, W., Liang, X., Li, X., Hatzihristidis, T., Guo, K., Li, X., Xiao, Y., Deng, Q., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.003 · Cited by 1
Özçelik, H., Yazır, Y., Duruksu, G., Kılıç, K. C., & Öztürk, A. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103274 · Cited by 2
The Rise and Rise of Type 1 and Type 2 Diabetes in Youth
DeBoer, M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s579743 · Cited by 1
Yen, H.-C., Lin, C.-H., & Lin, M.-C. (2026) · Pediatric Diabetes · doi:10.1155/pedi/3418021 · Cited by 1
Moscovitz, K., Bhavsar, D., & Tremlett, H. L. (2026) · Journal of Autoimmunity · doi:10.1016/j.jaut.2026.103526 · Cited by 1
Downes, G. M., Apley, K. D., Hu, G., Griffith, A. S., Genzano, C. B., Silva, C. R., Kendall, P. L., Creusot, R. J., & Berkland, C. J. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01428 · Cited by 2
Recent Advances in the Management of Type 1 Diabetes in Children
Beck, N. L. (2026) · Advances in Pediatrics · doi:10.1016/j.yapd.2025.12.012 · Cited by 1
Wei, H., Gou, W., Kim, J., Subramanian, S., Yeung, T., Chakraborty, P., Lotfy, A., Mehrotra, S., Berto, S., Strange, C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.032 · Cited by 2
Doytchinova, I. A., Dimitrov, I., Atanasova, M., Mihaylova, N., & Tchorbanov, A. I. (2026) · AI · doi:10.3390/ai7040140 · Cited by 1
Bergenstal, R. M., Willis, H. J., & Carlson, A. L. (2026) · Diabetes Care · doi:10.2337/dci26-0010 · Cited by 1
Syed, F., Krishnan, P., Chang, G., Rana, J., Langlais, S. R., Hati, S., Yamada, K., Lam, A. K., Talware, S., Aquino, J. D. C., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06720-7 · Cited by 13
Templeman, E. L., Thomas, N., Martin, S., Wherrett, D. K., REDONDO, M. J., Sherr, J., Petrelli, A., Jacobsen, L. M., Salami, F., Lonier, J., et al. (2026) · Diabetes Care · doi:10.2337/dc26-0446 · Cited by 1
Self-citationScreening Programs for Type 1 Diabetes in Youth: Evidence for Clinical Practice
Franceschi, R., Mozzillo, E., Marigliano, M., Maltoni, G., Maddaloni, E., Amendolara, R., Bernardini, L., Bonfanti, R., Ciambrelli, F., Candia, F. D., et al. (2026) · PEDIATRICS · doi:10.1542/peds.2025-075728 · Cited by 1
Global determinants and preventive intervention strategies in pediatric type 1 diabetes mellitus
Soliman, N. A., Soliman, A. T., Ahmed, S., Alyafei, F., AlHumaidi, N., Hamed, N., Alaaraj, N., Yassin, D. K., & Elawwa, A. (2026) · Journal of Pediatric Endocrinology and Diabetes · doi:10.25259/jped_56_2025 · Cited by 1
Positionspapier der DDG zum Typ-1-Diabetes-Screening
Blankenstein, O., Fritsche, A., Gölz, S., Haak, T., Hoffmann, G. F., Icks, A., Karges, B., Maio, G., Mohebbi, D., Neu, A., et al. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2884-8254 · Cited by 1
Chujo, D., Kawamura, T., Kikuchi, T., Imagawa, A., Koshiba, R., Maeda, Y., Hirota, Y., Ishii, A., Suzuki, J., Miura, J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113350 · Cited by 1
Hakimi, H., Yousefi, M. H., Mohammadi, Z., Komeili-Movahed, S., Afkhami, H., & Abdolmohammadi, M.-H. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00647-6 · Cited by 1
Early Assessment of Teplizumab Treatment Response Using Continuous Glucose Monitoring
Sari, K., Margolis, M. G., Smuel-Zilberberg, K., Weizman, S., Phillip, M., & Oron, T. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261458517 · Cited by 1
Flarup, P. B., Grabowski, D., DeCosta, P., Antvorskov, J. C., Pociot, F., & Jespersen, L. N. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1796164 · Cited by 1
Ngcobo, N. N., & Sibiya, N. H. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030048 · Cited by 1
Conti, M., Caputo, A., Montaperto, A., Geloso, V., Biundo, A., Puleo, A., Amodio, E., & Furnari, M. L. (2026) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2026.100222 · Cited by 1
REDONDO, M. J., Cuthbertson, D., Gupta, R., Siller, A. F., Devaraj, S., Vehik, K., Ismail, H. M., & Balasubramanyam, A. (2026) · Diabetes Care · doi:10.2337/dc26-0833 · Cited by 1
Klemann, C., & Kordonouri, O. (2026) · Diabetes Care · doi:10.2337/dc26-0543 · Cited by 1
Yu, D., Zhu, Y., Roca-Rivada, A., Guo, Z., Cheng, L., Weng, G., Toh, W. H., Martín-Vázquez, E., Buemi, A., Mourad, N. I., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c06440 · Cited by 1
Rosenzwajg, M., Hartemann, A., Halbron, M., Amouyal, C., Thivolet, C. H., Rigalleau, V., Fontaine, P., Mignot, B., Reynaud, R., Carel, J., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00191-9 · Cited by 1
Self-citationTyp-1-Diabetes: Früherkennung und Ansätze zur Prävention
Marcus, B. A., Achenbach, P., & Ziegler, A. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00668-x · Cited by 1
Self-citationKis, J. T., Engelmann, P., & Orban, T. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.9 · Cited by 1
Thompson, P. J., & Bhushan, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00008-0 · Cited by 1
Barisoni, L. M. C., & Luo, X. (2019) · Transplantation · doi:10.1097/tp.0000000000002972 · Cited by 1
Typ-1-Diabetes bei Kindern früh erkennen und präventiv handeln
Achenbach, P. (2022) · Diabetes aktuell · doi:10.1055/a-1839-8893 · Cited by 1
da Silva, W. F., Miranda, F. D. A. S., Cancado, B. L. B., Francescantonio, I. C. M., & Sobrinho, H. M. D. R. (2022) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e11230.2022 · Cited by 1
Früherkennung und Prävention des Typ-1-Diabetes
Hofelich, A., Marcus, B. A., & Achenbach, P. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-0894-1860 · Cited by 1
Prioritizing Early Disease Intervention
Caicedo, H. H., Darrow, J. J., Caicedo, J. C., & Pentland, A. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-023-00569-3 · Cited by 1
Pediatric diabetes diagnosis: New ISPAD guidelines 2022
Zdravković, V., Ješić, M. D., Bojić, V., Kovačević, S., Blagojević, J., Miolski, J., & Didić, N. (2023) · Galenika Medical Journal · doi:10.5937/galmed2305096z · Cited by 1
Stress and human health in diabetes: A report from the 19th Chicago Biomedical Consortium symposium
Mirmira, R., Kulkarni, R. N., Xu, P., Drossos, T., Varady, K., Knutson, K., Reutrakul, S., Martyn-Nemeth, P., Sargis, R., Wallia, A., et al. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.646 · Cited by 2
Recent Advances in Type 1 Diabetes: Teplizumab (Tzeild ® )
Fiano, K. S., Singh‐Franco, D., & Kwon, Y. M. (2024) · ADCES in Practice · doi:10.1177/2633559x241227639 · Cited by 1
Chernaya, M. E., Khalimov, Y. S., Volkova, A. R., Lisker, A. V., Nersesyan, A. A., Orlovskaya, A. D., Polushin, A. Y., Zalyalov, Y. R., & Kulagin, A. (2024) · Diabetes Mellitus · doi:10.14341/dm13089 · Cited by 1
Comparative Ability of Various Immunosuppressants as Adjuvants on the Activity of T1D Vaccine
Wang, X., Xie, M., Li, T., Shi, J., Wu, M., Zhang, S., Sun, J., & Hu, Y. (2024) · Vaccines · doi:10.3390/vaccines12101117 · Cited by 1
Swaby, R., Scudder, C. L., Randell, T. L., Marcovecchio, M. L., Gillespie, K. M., Liu, Y., Todd, J. A., Dunseath, G. J., Luzio, S. D., Dayan, C. M., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.23028.1 · Cited by 1
The Present and Future of Type 1 Diabetes Prevention: Teplizumab and Immunomodulators
Sohn, H., Kim, S., & Yoon, J.-H. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.4.210 · Cited by 1
Pillay, S., Pillay, A., & Kalhan, A. (2025) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2025.2464466 · Cited by 1
Díaz, J., da Fonseca, A. J., Yan, L., Liu, D., & Xie, L. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101496 · Cited by 1
Al-Okla, S., Al-Maqbali, S., Mutori, H. A., Al-Hinai, A., Bloushi, R. H. A., Aljabri, M. A., Alsenani, H. N., & Shafaee, M. A. (2025) · Diagnostics · doi:10.3390/diagnostics15182296 · Cited by 1
Odeh, R., Alassaf, A. A., Alhawari, H. H., Jafar, H. D., Awidi, A., Hani, F. B., & Sallam, M. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0402 · Cited by 1
Teplizumab delays onset of type 1 diabetes mellitus
Morris, A. W. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0233-3 · Cited by 1
Modulating the immune system to delay the clinical onset of type 1 diabetes
Sugahara, M., Tanaka, T., & Nangaku, M. (2019) · Kidney International · doi:10.1016/j.kint.2019.10.010 · Cited by 2
Inhibiting BRD4 to generate BETter T cell memory
Kasmani, M. Y., & Cui, W. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210877 · Cited by 1
Neue Wege zur Prävention des Typ-1-Diabetes bei Kindern
Kordonouri, O., Danne, T., & Lange, K. (2021) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-021-01274-x · Cited by 1
Simulating Screening for Risk of Childhood Diabetes: The Collaborative Open Outcomes tooL (COOL).
Ghalwash, M. F., Koski, E., Veijola, R., Toppari, J., Hagopian, W., Rewers, M., & Anand, V. (2021) · PubMed Central · Cited by 1
La prevenzione del diabete mellito di tipo 1
Nigi, L., Formichi, C., & Dotta, F. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01126-0 · Cited by 1
Cheah, Y. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.364 · Cited by 1
beginning of the end for insulin? – enter immunotherapy for T1DM
Dayan, C. M. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.369 · Cited by 1
Precision medicine in diabetes - current trends and future directions. Is the future now?
Szczerbiński, Ł., & Florez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00021-6 · Cited by 1
Early Diagnosis of Type 1 Diabetes – Useful or a Pyrrhic Victory?
Pozzilli, P., & Pieralice, S. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch2 · Cited by 1
Alhamar, G., Strollo, R., & Pozzilli, P. (2020) · Diabetes Care · doi:10.2337/dc20-0409 · Cited by 1
So, M., O’Rourke, C., Bahnson, H. T., Greenbaum, C. J., & Speake, C. (2020) · Diabetes Care · doi:10.2337/dci20-0016 · Cited by 1
Self-citationWherrett, D. K. (2021) · Diabetes Care · doi:10.2337/dci21-0018 · Cited by 1
Self-citationEndocrine disorders in infants, children, and adolescents
Shi, M., & PAGE, L. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818872-9.00050-9 · Cited by 1
Delgado, A. L., Preston‐Hurlburt, P., Lim, N., Sumida, T. S., Long, S. A., McNamara, J., Serti, E., Higdon, L. E., & Herold, K. C. (2023) · medRxiv · doi:10.1101/2023.07.11.23292344 · Cited by 1
Self-citationVerapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes
Hsu, N., Tsai, H., & Hsu, C. (2023) · JAMA · doi:10.1001/jama.2023.9110 · Cited by 1
Aydemir, Ö., Bailey, J. A., Agardh, D., Lernmark, Å., Noble, J. A., Svärd, A. A., Blankenhorn, E. P., Parikh, H. M., Ziegler, A., Toppari, J., et al. (2023) · eLife · doi:10.7554/elife.89068 · Cited by 1
Self-citationAydemir, Ö., Bailey, J. A., Agardh, D., Lernmark, Å., Noble, J. A., Svärd, A. A., Blankenhorn, E. P., Parikh, H. M., Ziegler, A., Toppari, J., et al. (2023) · eLife · doi:10.7554/elife.89068.1 · Cited by 1
Self-citationThe Extra-Islet Pancreas Supports Autoimmunity in Human Type 1 DiabetesPreprint
Barlow, G. L., Schürch, C. M., Bhate, S. S., Phillips, D. J., Young, A., Dong, S., Martinez, H., Kaber, G., Nagy, N., Ramachandran, S., et al. (2024) · eLife · doi:10.7554/elife.100535.1 · Cited by 1
Self-citationType 1 diabetes in children and adolescents
Hendriks, E., & Marcovecchio, M. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00184-9 · Cited by 1
T Cell Differentiation in Autoimmune Type 1 DiabetesPreprint
Schietinger, A., McBain, I. T., Hawley, K. M., & Miakicheva, S. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041592 · Cited by 2
Metadata
- Authors
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A.-G., & Greenbaum, C. J.
- Affiliations
- University of Miami (US)
- Children's Mercy Hospital (US)
- University of Minnesota (US)
- University of Iowa (US)
- ORCID
- Herold, Kevan C.
- Bundy, Brian N.
- Long, S. Alice
- Bluestone, Jeffrey A.
- DiMeglio, Linda A.
- Dufort, Matthew J.
- Gitelman, Stephen E.
- Gottlieb, Peter A.
- Krischer, Jeffrey P.
- Linsley, Peter S.
- Marks, Jennifer B.
- Moran, Antoinette
- Rodriguez, Henry
- Russell, William E.
- Schatz, Desmond
- Skyler, Jay S.
- Tsalikian, Eva
- Wherrett, Diane K.
- Ziegler, Anette-Gabriele
- Greenbaum, Carla J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 603-613
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6776880
- OpenAlex
- W2948104235
- Semantic Scholar
- a5198a4024a6f0aecc74d1501dd9fd2892f98796
- Cited by
- 1,189
- References
- 48
- Citations by year
- 2026: 186 · 2025: 209 · 2024: 211 · 2023: 181 · 2022: 123 · 2021: 148 · 2020: 98 · 2019: 32
- FWCI
- 60.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK107013, U01 DK107014, UC4 DK085466, UC4 DK097835, UC4 DK106993)
- JDRF
- American Diabetes Association
- The Immune Tolerance Network (UM1 AI09565)
- National Center for Research Resources, through Clinical Translational Science Awards (UL1TR000064, UL1TR000114, UL1TR000142, UL1TR000445, UL1TR001082, UL1TR001857, UL1TR001872, UL1TR002366, UL1TR002529, UL1TR002537)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- teplizumab, anti-CD3 monoclonal antibody, type 1 diabetes prevention, high-risk relatives, TIGIT, HLA-DR3, HLA-DR4, zinc transporter 8 antibodies, islet autoimmunity, lymphopenia
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Exanthema, Female, Glucose Tolerance Test, Humans, Lymphopenia, Male, Middle Aged, T-Lymphocytes, HLA-DR3 Antigen, HLA-DR4 Antigen, Proportional Hazards Models, CD3 Complex, Disease Progression, Lymphocyte Count, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
